Abstract：
:We compared concurrent chemoradiotherapy (CCRT) with docetaxel, cisplatin (CDDP), and 5-fluorouracil (5-FU) (TPF) with CCRT with CDDP, 5-FU, methotrexate and leucovorin (PFML) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) in terms of safety and efficacy on survival. A total of 100 patients were enrolled. The TPF group received CCRT with the TPF regimen [docetaxel (50 mg/m(2): day 1), CDDP (60 mg/m(2): day 4), and continuous 5-FU infusion (600 mg/m(2)/day: days 1-5)]. In the PFML group, patients received CCRT with the PFML regimen [CDDP (60 mg/m(2): day 4)], continuous 5-FU infusion (600 mg/m(2)/day: days 1-5), methotrexate (30 mg/m(2): day 1) and leucovorin (20 mg/m(2)/day: days 1-5)]. Both groups received 2 cycles of chemotherapy during definitive radiotherapy. The total radiation dose was between 66.6 and 70.2 Gray. The overall response rates after CCRT were 98 with 90% of a pathologically complete response (pCR) in the TPF group and 94 with 77% in the PFML group. For grade 3/4 adverse events, mucositis was more frequent in the PMFL group, and the TPF group showed a higher incidence of hematological toxicity. CCRT with TPF or PMFL for advanced SCCHN was tolerable and produced excellent survival rates.
journal_name
Cancer Chemother Pharmacoljournal_title
Cancer chemotherapy and pharmacologyauthors
Tsukuda M,Ishitoya J,Matsuda H,Horiuchi C,Taguchi T,Takahashi M,Nishimura G,Kawakami M,Watanabe M,Niho T,Kawano T,Ikeda Y,Sakuma Y,Shiono O,Komatsu Mdoi
10.1007/s00280-009-1217-0subject
Has Abstractpub_date
2010-09-01 00:00:00pages
729-36issue
4eissn
0344-5704issn
1432-0843journal_volume
66pub_type
杂志文章,随机对照试验abstract：:Nine children with poor-prognosis malignancies--seven with advanced neuroblastoma and two with metastatic Ewing's sarcoma--were given high doses of melphalan (HDM), 150 mg/m2 (3 patients) and 180 mg/m2 (6 patients), as a 'late intensification' agent combined with noncryopreserved autologous bone marrow transplants. Me...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章
doi：10.1007/BF00263898
更新日期：1985-01-01 00:00:00
abstract：BACKGROUND:Cancer has become one of the global health issues and it is the life-threatening disease characterized by unrestrained growth of cells. Despite various advances being adopted by chemotherapeutic management, the use of the current anticancer drugs such as Doxorubicin, Asparginase, Methotrexate, Vincristine re...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章
doi：10.1007/s00280-017-3414-6
更新日期：2017-11-01 00:00:00
abstract：:Saturable elimination of 5-FU is exhibited in rats during constant infusions. Over the range of 3-480 mg/m2/h, total-body clearance of 5-FU decreases from 600 ml/min/m2 to less than 90 ml/min/m2. Previously published values for catabolism of 5-FU by rat hepatocytes can be used to simulate the plasma concentrations of ...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章
doi：10.1007/BF00434346
更新日期：1985-01-01 00:00:00
abstract：PURPOSE:Low-dose methotrexate (MTX) therapy is the cornerstone treatment of acute lymphoblastic leukemia (ALL) and may enhance the activation of 6-mercaptopurine (6-MP) to 6-thioguanine nucleotides (6-TGN). Yet, data have established that high-dose MTX (HDMTX) hampers the accumulation of 6-TGN in red blood cells (RBC) ...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章
doi：10.1007/s00280-009-1205-4
更新日期：2010-09-01 00:00:00
abstract：:Twenty-seven patients with liver metastases from colorectal carcinoma were treated with 5-fluorouracil, adriamycin, and mitomycin C (FAM) by hepatic artery infusion (HAI) every 2-3 months for a maximum of eight courses. Median survival for all patients was 22 months. Toxicity was acceptable and consisted in severe mye...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章
doi：10.1007/BF00269032
更新日期：1984-01-01 00:00:00
abstract：:Paclitaxel is used as a single agent, and in combination with other drugs, as a standard of care in the treatment of squamous cell carcinoma of the head and neck (SCCHN). However, the use of paclitaxel for therapy of SCCHN may be accompanied by serious side effects. Paclitaxel is a known cytotoxic inhibitor of cell pr...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章
doi：10.1007/s00280-004-0929-4
更新日期：2005-07-01 00:00:00
abstract：:Thymidine (dThd) concentrations have been measured in the sera of normal subjects and solid tumor cancer patients by means of a sensitive high-pressure liquid chromatographic assay to determine whether natural and methotrexate (MTX)-induced fluctuations were large enough to alter the toxicity of MTX to marrow. The mea...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章
doi：10.1007/BF00434388
更新日期：1981-01-01 00:00:00
abstract：PURPOSE:The safety and efficacy of oral metronomic low-dose treosulfan chemotherapy in combination with the cyclooxygenase-2 (COX-2) inhibitor rofecoxib as a compound with antiangiogenic potential, a therapeutic regimen optimally targeting endothelial cells instead of tumor cells, were assessed in pretreated advanced m...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 临床试验,杂志文章
doi：10.1007/s00280-003-0678-9
更新日期：2003-11-01 00:00:00
abstract：PURPOSE:The effect of an anticancer treatment on tumor cell proliferation in vitro can be described as a three-dimensional surface where the inhibitory effect is related to drug concentration and treatment time. The analysis of this kind of response surface could provide critical information: for example, it could indi...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章
doi：10.1007/s00280-003-0688-7
更新日期：2003-12-01 00:00:00
abstract：PURPOSE:For the development of a safe and effective dual inhibitor of anticancer drug efflux transporters P-glycoprotein and multidrug resistance protein 1 (MRP1) to conquer multidrug resistance, we investigated the effects of dietary phytochemicals on the functions of P-glycoprotein and MRP1. METHODS:The effects of d...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章
doi：10.1007/s00280-007-0676-4
更新日期：2008-10-01 00:00:00
abstract：PURPOSE:Evasion to new treatments of advanced melanoma is still associated with a poor prognosis. Choosing the best combination of agents that can bypass resistance mechanisms remains a challenge. Sphaeropsidin A (Sph A) is a fungal bioactive secondary metabolite previously shown to force melanoma cells to undergo apop...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章
doi：10.1007/s00280-017-3293-x
更新日期：2017-05-01 00:00:00
abstract：PURPOSE:Metronomic chemotherapy, at a minimally toxic dose and with a frequent schedule, is a potentially novel approach to the control of advanced cancer disease via a different mechanism from maximum tolerable doses chemotherapy. Taking advantage of the potential effectiveness of metronomic therapy, tegafur/uracil (U...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 临床试验,杂志文章
doi：10.1007/s00280-006-0377-4
更新日期：2007-08-01 00:00:00
abstract：:A 62-year-old patient on long-term haemodialysis who developed an inoperable T2N3Mo squamous-cell carcinoma of the larynx was treated with weekly low-dose methotrexate (MTX) after failing to respond to radiotherapy. The patient was initially given one dose of 10 mg MTX (6 mg/m2) as a 1-h infusion, then he received thr...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章
doi：10.1007/s002800050528
更新日期：1996-01-01 00:00:00
abstract：:The rate of reaction of monochlorobimane with glutathione (GSH) was measured in native human mammary MCF-7 adenocarcinoma cells (MCF-7wt) and sublines displaying resistance to 4-hydroperoxycyclophosphamide (MCF-7hc) and adriamycin (MCF-7adr) prior to examination by epifluorescence and confocal microscopy. After a 60-m...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章
doi：10.1007/s002800050633
更新日期：1997-01-01 00:00:00
abstract：:Sparsomycin is a cytotoxic drug exhibiting a broad spectrum of in vitro activity against murine tumors and many tumor cell lines. It also appears to be a potent stimulator of the antitumor activity of cisplatin against L1210 leukemia in vivo. However, because of its toxicity, the antitumor activity of sparsomycin on m...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章
doi：10.1007/BF00253964
更新日期：1987-01-01 00:00:00
abstract：:Seventeen patients with malignant mesothelioma were treated in a phase II study with carboplatin, a cisplatin analogue without significant nephrotoxicity or neurotoxicity. The drug was given in a dose of 300-400 mg/m2 by i.v. infusion, repeating at 28-day intervals. One patient achieved a complete clinical and radiolo...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章
doi：10.1007/BF00273404
更新日期：1986-01-01 00:00:00
abstract：PURPOSE:Troxacitabine (BCH-4556, l-(-)-OddC, Troxatyl) is a novel beta- l-nucleoside analogue with potent antineoplastic activity both in vitro and in several tumor models in vivo, and is presently in phase II clinical trials. The combination of the cytosine analogues troxacitabine and araC (1-beta- d-arabinofuranosylc...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章
doi：10.1007/s00280-003-0699-4
更新日期：2003-12-01 00:00:00
abstract：UNLABELLED:Hypericin, a polycyclic aromatic dianthroquinone, is a natural pigment derived from the plant Hypericum perforatum (St John's Wort). The compound has been synthesized and shown to inhibit the growth of malignant glioma cell lines in vitro via inhibition of protein kinase C. Oral hypericin has entered clinica...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章
doi：10.1007/s002800000188
更新日期：2001-01-01 00:00:00
abstract：PURPOSE:This study was performed to determine the maximum tolerated dose (MTD) and toxicity of vinorelbine when used in combination with doxorubicin and methotrexate with leucovorin rescue in women with metastatic breast cancer. METHODS:Enrolled in the study were 23 women with metastatic breast cancer who had not rece...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 临床试验,杂志文章
doi：10.1007/s002800050929
更新日期：1999-01-01 00:00:00
abstract：:Characterization of the pharmacokinetics of 2-FLAA has been completed in seven patients receiving 18 or 25 mg/m2 daily X 5 of 2-FLAMP over 30 min. Assuming 2-FLAMP was instantaneously converted to 2-FLAA, the plasma levels of 2-FLAA declined in a biexponential fashion. Computer fitting of the plasma concentration-time...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章
doi：10.1007/BF00256699
更新日期：1986-01-01 00:00:00
abstract：:Carboplatin is an alternative for cisplatin in the treatment of urothelial cancers. A pharmacologically guided phase I study of carboplatin in combination with methotrexate (30 mg/m2) and vinblastine (4 mg/m2) was conducted in ten patients by increment of the area under the plasma concentration versus time curve (AUC)...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 临床试验,杂志文章
doi：10.1007/s002800050252
更新日期：1995-01-01 00:00:00
abstract：PURPOSE:Following a previously published pre-clinical validation, this phase I study evaluated the safety, maximum tolerated dose, anti-tumour activity and immune status of a gemcitabine-chloroquine combination as a first- or late-line treatment in patients with metastatic or unresectable pancreatic cancer. METHODS:In...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章
doi：10.1007/s00280-017-3446-y
更新日期：2017-11-01 00:00:00
abstract：PURPOSE:To further improve the prognosis of esophageal cancer patients, it is necessary to investigate new treatment strategies. The purposes of this study were to retrospectively assess the safety and efficacy of neoadjuvant chemoradiotherapy (CRT) with docetaxel/cisplatin/5-fluorouracil (DCF) (DCF-RT) in patients wit...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章
doi：10.1007/s00280-018-03764-4
更新日期：2019-03-01 00:00:00
abstract：PURPOSE:It remains challenging to identify patients at risk of anthracycline-induced cardiotoxicity. To better understand the different risk-stratifying approaches, we evaluated (123)I-metaiodobenzylguanidine ((123)I-mIBG) scintigraphy and its interrelationship with conventional echocardiography, 2D strain imaging and ...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章
doi：10.1007/s00280-015-2874-9
更新日期：2015-11-01 00:00:00
abstract：:Imidazoacridinones are a new class of highly potent antineoplastic agents synthesised at the Technical University of Gdansk. The pharmacophoric alkyldiamine group, which is also present in anthracenediones (e.g. ametantrone, mitoxantrone), has been shown to be responsible for their antineoplastic activity. In view of ...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章
doi：10.1007/s002800050445
更新日期：1996-01-01 00:00:00
abstract：PURPOSE:The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) is approved for cancer treatment. We investigated whether gefitinib treatment can enhance human EGF (hEGF) uptake in vitro, thereby increasing the potential of hEGF as a vehicle for EGFR-targeted therapy. METHODS:W...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章
doi：10.1007/s00280-013-2198-6
更新日期：2013-08-01 00:00:00
abstract：PURPOSE:Bevacizumab (BV) prolongs the survival of colorectal cancer patients when combined with irinotecan (CPT-11)-based regimens. In the AVF2107g study, the area under the curve (AUC) ratio for bolus CPT-11/5-fluorouracil (5-FU)/leucovorin (LV) (IFL) with the BV arm to bolus IFL with placebo indicated that SN-38 conc...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 临床试验,杂志文章
doi：10.1007/s00280-009-1051-4
更新日期：2010-02-01 00:00:00
abstract：PURPOSE:Nephrotoxicity is one of the major dose-limiting side-effects of cisplatin (DDP). The disproportionate accumulation of cisplatin in kidney tissue may play an important role, however, therapeutic measures to prevent this prime cause of nephrotoxicity are not available. Because certain amino acids (AAs) have been...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章
doi：10.1007/PL00006741
更新日期：2000-01-01 00:00:00
abstract：PURPOSE:Anti-angiogenic agents combined with histone deacetylase inhibitors act synergistically in vitro and in vivo. We conducted a phase I study of the combination of the anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. METHODS:Bevacizumab w...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章
doi：10.1007/s00280-014-2384-1
更新日期：2014-03-01 00:00:00
abstract：PURPOSE:This phase II study was performed to evaluate the efficacy and safety of cisplatin/pemetrexed combined with 15 mg/kg of bevacizumab followed by pemetrexed/bevacizumab maintenance therapy as first-line chemotherapy in advanced non-squamous non-small cell lung cancer (NSCLC) limited to epidermal growth factor rec...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章
doi：10.1007/s00280-018-3573-0
更新日期：2018-06-01 00:00:00
